• 1. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 2. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 3. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 4. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 5. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455

Recent Advances in the Study of 2-(4-Ethoxycarbonylphenyl)benzoic acid (CAS: 1261941-50-7) in Chemical Biology and Pharmaceutical Research

2-(4-Ethoxycarbonylphenyl)benzoic acid (CAS: 1261941-50-7) is a compound of growing interest in the field of chemical biology and pharmaceutical research. Recent studies have highlighted its potential as a versatile building block in the synthesis of novel bioactive molecules, particularly in the development of anti-inflammatory and anticancer agents. This research brief aims to summarize the latest findings related to this compound, focusing on its chemical properties, biological activities, and potential therapeutic applications.

One of the key areas of investigation has been the role of 2-(4-Ethoxycarbonylphenyl)benzoic acid in modulating inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit significant inhibitory effects on cyclooxygenase-2 (COX-2), an enzyme implicated in inflammation and pain. The study utilized molecular docking simulations and in vitro assays to elucidate the binding interactions between the compound and the COX-2 active site, providing valuable insights for the design of next-generation anti-inflammatory drugs.

In addition to its anti-inflammatory properties, recent research has explored the anticancer potential of 2-(4-Ethoxycarbonylphenyl)benzoic acid. A team of researchers from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters that this compound can induce apoptosis in certain cancer cell lines by disrupting mitochondrial function. The study employed flow cytometry and Western blotting to confirm the activation of apoptotic pathways, suggesting that further optimization of this scaffold could yield promising chemotherapeutic agents.

The synthetic utility of 2-(4-Ethoxycarbonylphenyl)benzoic acid has also been a focus of recent investigations. A 2024 paper in Organic Letters described an efficient, one-pot synthesis method for this compound, which significantly improves yield and reduces production costs compared to traditional approaches. This advancement is particularly relevant for industrial-scale applications, where cost-effective synthesis routes are critical for commercialization.

Looking ahead, researchers are exploring the potential of 2-(4-Ethoxycarbonylphenyl)benzoic acid as a precursor for the development of targeted drug delivery systems. Preliminary studies suggest that its carboxylic acid moiety can be readily conjugated to various drug carriers, enabling site-specific delivery of therapeutic agents. This approach could minimize off-target effects and enhance treatment efficacy, particularly in complex diseases such as cancer and autoimmune disorders.

In conclusion, the growing body of research on 2-(4-Ethoxycarbonylphenyl)benzoic acid (CAS: 1261941-50-7) underscores its importance as a multifunctional compound in pharmaceutical development. Its demonstrated biological activities, coupled with its synthetic accessibility, make it a valuable scaffold for drug discovery. Future studies should focus on optimizing its pharmacokinetic properties and exploring its potential in combination therapies to fully realize its therapeutic potential.

• 87555-72-4([1,1'-Biphenyl]-3-carboxylic acid, 2,4-dimethyl-, ethyl ester)
• 694443-36-2(4-(methoxycarbonyl)benzyl 1,1'-biphenyl-2-carboxylate)
• 4445-34-5(Dibenz(c,e)oxepine-5(7H)-one)
• 76331-32-3([1,1':2',1''-Terphenyl]-4'-carboxylicacid, 3',6'-dimethyl-5'-phenyl-, ethyl ester (9CI))
• 18263-57-5(ethyl 2'-formyl[1,1'-biphenyl]-2-carboxylate)
• 1261933-89-4(3-(4-Ethoxycarbonylphenyl)-2-methylbenzoic acid)
• 192637-88-0(Ethyl 2'-methyl[1,1'-biphenyl]-2-carboxylate)
• 5807-65-8(Diethyl biphenyl 2,2'-dicarboxylate)
• 206647-52-1([1,1'-BIPHENYL]-2,2',6,6'-TETRACARBOXYLIC ACID, MONO(PHENYLMETHYL) ESTER)
• 71871-12-0([1,1'-BIPHENYL]-2,2'-DICARBOXYLIC ACID, 6,6'-DIMETHYL-, DIETHYL ESTER)